Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$104.77 USD
-0.47 (-0.45%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $104.41 -0.36 (-0.34%) 6:52 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 521 - 534 ( 534 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Organic Growth Plus Positive Currency Yields Double-Digit Growth in All Major Segments
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Med Tech Review and Preview: Big Players Navigate Through Maturing Markets, While BSX Woes
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
MERGERS & ACQUISITIONS
Provider: WALL STREET ACCESS CORP.
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
FDA Wants More Info Before Approving CERTRIAD No Clue on Potential Timing, But Very Modest Financial Impact A Sign of the Regulatory Times.
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
ACCORD Results Should Not Rattle Investors Much Longer - Meanwhile, EVEREST II, Latest ABSORB Data Likely to Boost Confidence in Vascular Opportunity -- Expect Stock to Gain Momentum After ACC
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
New product launches & strong long term fundamentals paint robust outlook.Better than industry average growth prospects justify stock?s moderate premium to Global Pharma peers.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Medical - Drugs
Company: Abbott Laboratories
Industry: Medical - Drugs
Company: Abbott Laboratories
Industry: Medical - Drugs
Solid Q4 Performance, On-Target 2010 Guidance, and Lots of Moving Parts to Sort Through as a New Year Begins
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Medical - Drugs
Company: Abbott Laboratories
Industry: Medical - Drugs
December Quarter Review and 2010 Preview: The Graying of the Cardiac Devices Market
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Medical - Drugs
Company: Abbott Laboratories
Industry: Medical - Drugs
A Very Well-Timed Approval for XIENCE in Japan - Launch Likely to Get a Big Lift from Lancet Article (COMPARE), Pending NEJM Article (SPIRIT IV)
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Medical - Drugs
New Spotlight on XIENCE vs. TAXUS Comparison Likely to Boost ABT, Hurt BSX
Provider: WEDBUSH SECURITIES INC.